Article Data

  • Views 212
  • Dowloads 100

Original Research

Open Access

Primary fallopian tube carcinoma: a retrospective clinicopathologic study

  • P. Singhal1
  • K. Odunsi1
  • K. Rodabaugh1
  • D. Driscoll2
  • S. Lele1,*,

1Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA

2Department of Biostatics, Roswell Park Cancer Institute, Buffalo, NY, USA

DOI: 10.12892/ejgo20060116 Vol.27,Issue 1,January 2006 pp.16-18

Published: 10 January 2006

*Corresponding Author(s): S. Lele E-mail:

Abstract

Introduction: Primary fallopian tube carcinoma is a rare tumor. The aim of this study was to evaluate clinical characteristics and management of fallopian tube malignancies at a large tertiary care cancer institute.

Methods: A retrospective review of the Tumor Registry was conducted to identify all primary fallopian tube carcinomas between 1980 and 2001. Medical charts were retrospectively reviewed. Primary endpoints were overall survival and disease recurrence.

Results: Thirty-five patients had histology consistent with fallopian tube carcinoma. The median age at diagnosis was 56 years. The most common signs or symptoms were abnormal vaginal bleeding (29%) and abdominal/pelvic mass (26%). The most common histology was adenocarcinoma in 16 (46%) patients. Five patients (14%) were Stage I, seven patients (20%) Stage II, 17 patients (49%) Stage III and six patients (17%) Stage IV. Thirty-two (91%) patients received adjuvant chemotherapy and 77% received platinum-based chemotherapy. Twenty-seven (77%) patients underwent second-look surgery, of which 17 patients (63%) were positive for disease. The 5-year survival rate was 64% for Stage I, 42% for Stage II, 32% for Stage III, and 17% for Stage IV.

Conclusions: Fallopian tube malignancies are rare and carry a poor prognosis. More extensive research needs to be performed to have definitive etiologic, diagnostic and treatment guidelines.

Keywords

Fallopian tube cancer; Second-look surgery; Chemotherapy

Cite and Share

P. Singhal,K. Odunsi,K. Rodabaugh,D. Driscoll,S. Lele. Primary fallopian tube carcinoma: a retrospective clinicopathologic study. European Journal of Gynaecological Oncology. 2006. 27(1);16-18.

References

[1] Brown K.E., Kapp D.S., Schwartz P.E., Merino M.: "Fallopian tube carcinoma". Int. J. Radiat. Oneal. Biol. Phys., 1985, 11, 583.

[2] Sedlis A.: "Primary carcinoma of the fallopian tube". Obstet. Gynecol. Surv., 1961, 16,209.

[3] Eddy G.L., Copeland L.J., Gershenson D.M., Atkinson E.N., Wharton J.T., Rutledge F.N.: "Fallopian tube carcinoma". Obstet. Gynecol., 1984, 64, 546.

[4] Semrad S.D., Hardee G.E., Hardee M.M., Moore J.N.: "Flunixin meglumine given in small doses: pharmacokinetics and prostaglandin inhibition in healthy horses". Am. J. Vet. Res., 1985, 46, 2474.

[5] Roberts J.A., Lifshitz S.: "Primary adenocarcinoma of the fallopian tube". Gynecol. Oneal., 1982, 13, 301.

[6] Raju K.S., Barker G.H., Wiltshaw E.: "Primary carcinoma of the fallopian tube. Report of 22 cases". Br. J. Obst et. Gynaecol., 1981, 88, 1124.

[7] Ozols R.F., Eifel P.J.: "Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma". Principles and Practice of Oncology, 6th editon, Philadelphia, Lippincott Williams & Wilkins, 2001.

[8] McMurray E.H., Jacobs A.J., Perez C.A., Camel H.M., Kao M.S., Galakatos A.: "Carcinoma of the fallopian tube. Management and sites of failure". Cancer, 1986, 58, 2070.

[9] Lacy M.Q., Hartmann L.C., Keeney G.L., Cha S.C., Wieand H.S., Podratz K.C. et al.: "c-erbB-2 and p53 expression in fallopian tube carcinoma". Cancer, 1995, 75, 2891.

[10] Hu C.Y., Taymor M.L., Hertig A.T.: "Primary carcinoma of the fallopian tube". Am. J. Obstet. Gynecol., 1950, 59, 58.

[11] Creasman W.T.: "Revision in classification by International Federation of Gynecology and Obstetrics". Am. J. Obstet. Gynecol., 1992, 167, 857.

[12] Fleming C.J., Henson D.E., Hutter R.V.P., Kennedy B.J., Murphy G.P.: American Joint Committee on cancer staging. AJCC Cancer Staging Manual, 5th edition, Philadelphia, Lippincott-Raven, 1997.

[13] Kaplan E. L., Meir P.: "Nonparametric estimation from incomplete Observations". J. Amer. Stat. Assoc., 1958, 53, 457.

[14] Podratz K.C., Podczaski E.S., Gaffey T.A., O'Brien P.C., Schray M.F., Malkasian G.D. Jr.: "Primary carcinoma of the fallopian tube". Am. J. Obstet. Gynecol., 1986, 154, 1319.

[15] Hellstrom A.C., Silfversward C., Nilsson B., Pettersson F.: "Carcinoma of the fallopian tube. A clinical and histopathologic review. T he Radiumhemmet series". Int. J. Gynecol. Cancer., 1994, 6, 395.

[16] Scully R.E. C.P.: "Tumors of the ovary,m aldeveloped gonads,f allopian tube and broad ligament". Washington, DC, Armed Forces Institute of Pathology, 1998.

[17] King A., Seraj I.M., Thrasher T., Slater J., Wagner R.J.: "Fallopian tube carcinoma: a clinicopathological study of 17 cases". Gynecol. Oneal.,1 989,3 3, 351.

[18] Maxson W.Z., Stehman F.B., Ulbright T.M., Sutton G.P., Ehrlich C.E.: "Primary carcinoma of the fallopian tube: evidence for activity of cisplatin combination therapy". Gynecol. Oneal., 1987, 26, 305.

[19] Harrison C.R., Averette H.E., Jarrell M.A., Penalver M.A., Donato D., Sevin B.U.: "Carcinoma of the fallopian tube: clinical management". Gynecol. Oneal., 1989, 32, 357.

[20] Peters W.A., 3rd, Andersen W.A., Hopkins M.P., Kumar N.B., Morley G.W.: "Prognostic features of carcinoma of the fallopian tube". Obstet. Gynecol., 1988, 71, 757.

[21] Eddy G.L., Copeland L.J., Gershenson D.M.: "Second-look laparotomy in fallopian tube carcinoma". Gynecol. Oneal., 1984, 19, 182.

[22] Barakat R.R., Rubin S.C., Saigo P.E., Lewis J.L. Jr., Jones W.B., Curtin J.P.: "Second-look laparotomy in carcinoma of the fallopian tube". Obstet. Gynecol., 1993, 82, 748.

[23] Cormio G., Gabriele A., Maneo A., Marzola M., Lissoni A., Mangioni C.: "Second-look laparotomy in the management of fallopian tube carcinoma". Acta. Obstet. Gynecol. Scand.,1 997,7 6, 369.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top